

Figure S1: Survival analysis in strata of integrase inhibitors (INI) and non-INI-based regimens showed a significantly higher rate of discontinuations due to CNS-AE in INI (logrank $p < 0.0001$).




Table S1. Crude and adjusted hazard ratio (HR) for discontinuation due to central nervous system events.

Variable	Crude HR	95% CI	P	Adjusted HR**	95% CI	P
Sex F (ref. M)	1.28	0.77-2.16	0.34			
Age (by 1 year)	1.02	1.00-1.04	0.10			
Age (ref. ≤50 years)	1.97	1.21-3.21	0.006	1.57	0.94-2.62	0.08
Weight (by 5 Kg)	0.99	0.91-1.08	0.89			
Ethnicity (ref. Caucasian)	1.23	0.53-2.85	0.62			
HCV-Ab+ (ref. HCV-Ab negative)	1.14	0.67-1.92	0.63			
Naïve (ref. experienced)	2.06	1.21-3.51	0.008	2.44	1.39-4.28	0.002
CDC stage (ref. A)						
B	0.88	0.50-1.56	0.66			
C	0.75	0.41-1.36	0.34			
CDC stage: chi-square for trend	0.92		0.34			
CD4 (ref. <250)						
250-499	1.32	0.65-2.69	0.44	1.28	0.64-2.61	0.47
500-749	1.30	0.59-2.84	0.51	1.11	0.49-2.51	0.80
≥750	2.65	1.34-5.25	0.005	2.28	1.08-4.68	0.03
CD4 class: chi-square for trend	7.02		0.008	3.66		0.055
Baseline psychiatric disorder (ref. no) *	2.35	1.16-4.75	0.017	2.05	1.01-4.18	0.049
Study cohort (ref. Dolutegravir)						
Lopinavir	0.09	0.02-0.40	0.0009	0.12	0.03-0.52	0.005
Atazanavir	0.06	0.01-0.42	0.004	0.08	0.01-0.61	0.015
Darunavir	0.09	0.02-0.37	0.0008	0.11	0.03-0.44	0.002
Rilpivirine	0.63	0.29-1.33	0.22	0.65	0.30-1.43	0.29
Raltegravir	0.30	0.12-0.75	0.01	0.38	0.15-0.98	0.045
Elvitegravir	0.28	0.09-0.89	0.03	0.29	0.09-0.94	0.036
Bictegravir	0.67	0.28-1.59	0.36	0.67	0.28-1.60	0.37